Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
INSILICO's UAE Team Nominates First AI-Enabled Preclinical Drug Candidate
Recommend 0 Positive 1 Negative 1 |
||||
|
||||
|
INSILICO (03696.HK) announced that Insilico Medicine has officially nominated ISM0387, an MTA-cooperative PRMT5 inhibitor, as a pre-clinical candidate (PCC). Discovered locally by Insilico Medicine’s UAE team using the Company’s proprietary Pharma.AI platform, the program completed the early discovery workflow - from molecular design to optimization - in the UAE within less than 12 months, during which a series of hit compounds was generated within 30 days, followed by the completion of lead compound optimization within 6 months. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
